Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30685515 | 0.96 | AURKA (0.42) | AURKAKDRKDM4CADRA1DADRA1A | |
| SCHEMBL24922603 | 0.72 | NPC1 (0.44) | AURKAKDRKDM4CCDK5CDK5R1 | |
| SCHEMBL7365394 | 0.71 | KDR (0.37) | AURKAKDRKDM4CCDK5MEN1 | |
| SCHEMBL1298623 | 0.71 | IDO1 (0.39) | POLB | |
| SCHEMBL17850816 | 0.70 | — | — | |
| SCHEMBL1551082 | 0.68 | AURKA (0.53) | AURKAKDRADRA1DADRA1AADRA1B | |
| SCHEMBL7105096 | 0.68 | CSNK1A1 (0.45) | AURKAKDRKDM4CADRA1AMEN1 | |
| SCHEMBL15416821 | 0.68 | KDR (0.47) | AURKAKDRKDM4CADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL4436439 | 0.67 | AURKA (0.51) | AURKAKDRADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL4430517 | 0.67 | AURKA (0.51) | AURKAKDRADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-11512095-B2 | BCL6 inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-29 | — | — | US | disclosed |
| WO-2021080359-A1 | BICYCLIC COMPOUND AND USE THEREOF | 에스케이바이오팜 주식회사 | 2021-04-29 | — | — | WO | disclosed |
| US-8193430-B2 | Methods for separating carbon nanotubes | THE UNIVERSITY OF CONNECTICUT (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100044230-A1 | METHODS FOR SEPARATING CARBON NANOTUBES | UNIVERSITY OF CONNECTICUT (US) | 2010-02-25 | — | — | US | disclosed |
| US-20090191552-A1 | Novel Human Acidic Mammalian Chitinase and Use Thereof | MERCK SHARP & DOHME CORP. | 2009-07-30 | — | — | US | disclosed |
| EP-2038409-A2 | NOVEL HUMAN ACIDIC MAMMALIAN CHITINASE AND USE THEREOF | Merck & Co., Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008002548-A2 | NOVEL HUMAN ACIDIC MAMMALIAN CHITINASE AND USE THEREOF | MERCK & CO., INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-1307453-A2 | DIHYDRONAPHTHYRIDINE- AND DIHYDROPYRROLOPYRIDINE-DERIVATED COMPOUNDS AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010164-A2 | DIHYDRONAPHTHYRIDINE- AND DIHYDROPYRROLOPYRIDINE-DERIVATED COMPOUNDS AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100044230-A1 | METHODS FOR SEPARATING CARBON NANOTUBES | FSCN1, TTPA, FLNB | AURKA 3808/4885KDR 3055/4885KDM4C 3923/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | AURKA 289/4885KDR 2548/4885KDM4C 1789/4885 |
| US-11512095-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | AURKA 2537/4885KDR 4193/4885KDM4C 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.